此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

ZKARE®凝胶及其辅助产品ZKAPI®治疗慢性溃疡的有效性和安全性:一项前瞻性、随机、对照临床研究。

2026年11月2日 更新者:i+Med S.Coop.

ZKARE®凝胶及其辅助剂ZKAPI®治疗慢性溃疡的有效性和安全性:一项前瞻性、随机、对照临床研究。

This prospective, randomized, single-blind, controlled clinical investigation evaluates the efficacy and safety of ZKARE®, a topical polymeric gel dressing, and its accessory applicator ZKAPI®, for the treatment of chronic, hard-to-heal ulcers. The study includes 134 ulcers of different etiologies-pressure ulcers, neuropathic diabetic foot ulcers, and venous leg ulcers-meeting predefined selection criteria. Participants are randomized to receive either ZKARE® in addition to standard wound care or standard care alone.

The primary efficacy endpoint is the change in wound condition assessed through the RESVECH 2.0 scale, recorded at baseline and throughout treatment and follow-up visits. The primary safety endpoint is the incidence of serious adverse events (SAEs). Secondary outcomes include percentage and rate of wound closure, total closure rate, estimated time to full closure, quality-of-life measures (DLQI), patient satisfaction, investigator global assessment, cost-effectiveness, and product usability. The study aims to generate evidence on the performance, safety, and clinical usefulness of ZKARE® for chronic wound management.

研究概览

详细说明

Chronic ulcers such as pressure ulcers, neuropathic diabetic foot ulcers and venous leg ulcers frequently fail to follow normal healing phases and require comprehensive management. Many existing dressings act through a single mechanism and are limited in effectiveness for complex or exudative wounds. ZKARE® is a sterile, biocompatible polymeric gel intended for topical use that provides a moist microenvironment, absorbs excess exudate and contributes to bacterial control. The product is applied using ZKAPI®, a sterile Luer-Lock applicator designed to improve precision and ease of administration.

This prospective, randomized, single-blind, controlled clinical investigation compares ZKARE® plus standard care with standard care alone in 134 chronic ulcers of different etiologies. Patients may contribute more than one ulcer if lesions are independent. After informed consent, ulcers are randomized, and treatment sessions follow routine clinical practice, with ZKARE® added only in the investigational arm. Blinding is maintained by preventing direct visualization of the wound and through iso-appearance of materials. Follow-up visits occur at approximately 2, 4, 8 and 12 weeks.

The primary efficacy endpoint is the change in RESVECH 2.0 score, recorded at baseline, each treatment session and all follow-up visits; a ≥2-point improvement at Week 4 is considered clinically relevant. The primary safety endpoint is the incidence of serious adverse events. Secondary outcomes include percentage and rate of wound closure, total closure rate, estimated time to full closure, DLQI, patient satisfaction, investigator global assessment, usability and cost-effectiveness, as well as non-serious adverse events.

Group comparisons use appropriate statistical tests for categorical and continuous variables, repeated-measures analyses and ANCOVA where applicable, under an intention-to-treat approach. The sample size of 134 ulcers gives 80% power to detect expected differences in RESVECH 2.0 change. The study aims to evaluate the clinical performance and safety of ZKARE® and ZKAPI® in the treatment of chronic hard-to-heal ulcers

研究类型

介入性

注册 (估计的)

134

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Adult patients (≥18 years).
  • Presence of at least one chronic hard-to-heal ulcer, including any of the following etiologies: Grade II, III or IV pressure ulcers; neuropathic diabetic foot ulcers (grade I, II or III), Wagner Grade I-III or Texas 0, I, II, III / Stage B; class C6/C6r venous leg ulcers measured with CEAP scale ; neuro-ischaemic ulcers with adequate distal perfusion (ABI/ITB ≥ 0.7-0.89; mild PAD); mixed-etiology venous ulcers and any chronic lower-limb lesion with palpable distal pulses.
  • Ulcer size between 1 cm² and 100 cm².
  • Ability and willingness to comply with all study visits and procedures according to the clinical protocol.
  • Ability to understand and sign the informed consent, obtained before performing any protocol-specific procedures.

Exclusion Criteria:

  • Ulcers of etiologies not listed in the inclusion criteria.
  • Ischaemic, neoplastic or atypical ulcers.
  • Severe comorbidities judged to compromise safety or study compliance, including: severe malnutrition, palliative/terminal status, severe anemia, decompensated heart failure, chronic kidney disease stage III/IV or in dialysis.
  • Ulcers with moderate-severe or severe infection per PEDIS-IDSA infection grading scale.
  • Known allergy or sensitivity to any component of the investigational product.
  • Any condition that, in the investigator's opinion, may compromise patient safety or adherence to the protocol.
  • Pregnancy or planned breastfeeding.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:ZKARE®

Participants assigned to this arm receive standard wound care plus topical application of the investigational gel ZKARE®, applied using the ZKAPI® applicator during each wound-care session.

ZKARE® is applied topically after routine wound cleansing and debridement. Using the sterile ZKAPI® applicator, the gel is distributed to fully cover the wound bed, including irregular or cavitated areas. The treated wound is then covered with the appropriate secondary dressing following standard clinical practice. The application is repeated at each treatment session until complete closure or the end of the 12-week follow-up period. All sessions include RESVECH 2.0 scoring, standardized photographs, and safety assessments

有源比较器:Standard Wound Care

Participants assigned to this arm receive standard wound management according to routine clinical practice, without the use of the investigational product.

Standard care includes wound cleansing, debridement when required, and selection of secondary dressings according to wound characteristics such as exudate level, infection status, depth, and perilesional skin condition. No investigational gel is applied. At each treatment visit and follow-up time point, standardized wound photographs, RESVECH 2.0 scoring, closure metrics, and safety assessments are recorded according to the same schedule as the investigational arm.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
RESVECH Scale 2.0
大体时间:12 weeks or wound healing

Change in the RESVECH 2.0 wound assessment scale, which evaluates wound size, depth, granulation tissue quality, exudate amount/type, clinical signs of infection/inflammation, and perilesional skin condition.

Measured at baseline and at each treatment and follow-up visit until complete closure or at week 12. A ≥2-point improvement at week 4 is considered clinically relevant.

12 weeks or wound healing
Incidence of Serious Adverse Events (SAEs)
大体时间:12 weeks

Incidence, frequency, and nature of serious adverse events during the study.

12 weeks

次要结果测量

结果测量
措施说明
大体时间
Wound Closure Rate (mm²/day)
大体时间:12 weeks

Rate of epithelialization based on the area healed divided by the time since treatment initiation.

Assessed at each treatment and follow-up visit.

12 weeks
Percentage of Wound Closure (%)
大体时间:12 weeks

Percentage reduction of the initial wound area at each assessment. A ≥30% reduction by week 4 is considered clinically relevant.

Kaplan-Meier curves may be used to evaluate closure thresholds (≥30%-90%).

12 weeks
Total Wound Closure (%)
大体时间:12 weeks

Percentage of wounds achieving complete epithelialization.

12 weeks
Estimated Time to Full Closure (days)
大体时间:12 weeks

For wounds not completely healed by week 12, linear regression based on closure rate is used to estimate time to complete healing.

12 weeks
Cost-Effectiveness Analysis (Healthcare Resources Used)
大体时间:12 weeks

Quantification of materials, products, consumables, and healthcare professional time in each treatment session.

Reported as €/patient.

12 weeks
Dermatology Life Quality Index (DLQI) Score
大体时间:12 weeks

Change in DLQI score (0-30), with higher scores indicating worse dermatology-related quality of life.

12 weeks
Patient Satisfaction (Likert Scale)
大体时间:12 weeks

Patient satisfaction rated at study end (Very dissatisfied, dissatisfied, neutral, satisfied and very satisfied).

Outcome to be reported as the percentage of "Satisfied" + "Very satisfied" answers.

12 weeks
Investigator Global Assessment (IGA)
大体时间:12 weeks

Clinical impression of overall wound evolution (Worsening / No improvement / Mild improvement / Significant improvement).

Outcome to be reported as the percentage of mild or significant improvement achievement.

12 weeks
Incidence of Non-Serious Adverse Events (AEs)
大体时间:12 weeks

Recording of the incidence and nature of all non-serious adverse events.

12 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年11月14日

初级完成 (估计的)

2027年3月1日

研究完成 (估计的)

2027年8月1日

研究注册日期

首次提交

2026年2月5日

首先提交符合 QC 标准的

2026年2月5日

首次发布 (实际的)

2026年2月12日

研究记录更新

最后更新发布 (实际的)

2026年11月4日

上次提交的符合 QC 标准的更新

2026年11月2日

最后验证

2026年2月1日

更多信息

与本研究相关的术语

其他研究编号

  • ZKARE-PIC01-2025

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅